| Perin, Emerson |
ACORD, NCT00117936: Fibroblast Growth Factor-1 (FGF-1) for the Treatment of Coronary Heart Disease |
|
|
| Not yet recruiting | 2 | 150 | NA | Human Recombinant Fibroblast Growth Factor-1 (FGF 1-141) - low dose, Human Recombinant Fibroblast Growth Factor-1 (FGF1-141) - high dose, Placebo | CardioVascular BioTherapeutics, Inc. | Coronary Disease, Coronary Heart Disease, Myocardial Ischemia, Coronary Arteriosclerosis | 03/22 | 03/23 | | |
CATO, NCT06145035: Single or Repeated Intravenous Administration of umbiliCAl Cord Mesenchymal sTrOmal Cells in Ischemic Cardiomyopathy |
|
|
| Recruiting | 2 | 60 | US | umbilical cord-derived mesenchymal stromal cells (UC-MSCs) | Roberto Bolli, University of Miami, University of Texas, United States Department of Defense | Ischemic Heart Disease | 01/26 | 01/26 | | |
NCT05592275: A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF) |
|
|
| Active, not recruiting | 2 | 456 | Europe, Canada, Japan, US, RoW | LY3540378, Placebo | Eli Lilly and Company | Heart Failure, Heart Failure With Preserved Ejection Fraction | 01/25 | 01/25 | | |
DCMII, NCT04476901: Administration of Allogeneic-MSC in Patients with Non-Ischemic Dilated Cardiomyopathy |
|
|
| Recruiting | 2 | 136 | US | allogeneic human mesenchymal stem cells (hMSCs), Placebo | Joshua M Hare, United States Department of Defense, The University of Texas Health Science Center, Houston | Non-ischemic Dilated Cardiomyopathy | 12/25 | 12/25 | | |
NCT00314366: Intramyocardial Injection of Autologous Aldehyde Dehydrogenase-Bright Stem Cells for Therapeutic Angiogenesis (FOCUS Br) |
|
|
| Completed | 1 | 21 | US | Stem Cell Therapy, NOGA Myostar catheter, Control (plasma) | Texas Heart Institute, CHI St. Luke's Health, Texas, Aldagen | Coronary Artery Disease | 08/09 | 08/23 | | |
| Recruiting | N/A | 380 | Canada, US | Arm 1: treatment with Neovasc Reducer, Arm 2 (control): Implantation procedure with no device implanted, Arm 3 (unblinded, non-randomized): Single arm registry | Neovasc Inc., Shockwave Medical, Inc. | Refractory Angina | 06/25 | 12/28 | | |
| Bracey, Arthur |
| Completed | 3 | 3506 | Europe, Canada, US, RoW | Red Blood Cell Transfusion | Rutgers, The State University of New Jersey, University of Pittsburgh, National Heart, Lung, and Blood Institute (NHLBI) | Myocardial Infarction, Anemia | 05/23 | 10/23 | | |
RedeS, NCT03037164: INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections |
|
|
| Recruiting | 3 | 800 | US | INTERCEPT Blood System for Red Blood Cells, Conventional (Control) | Cerus Corporation | Anemia | 10/25 | 01/26 | | |
| Callahan, Christine C |
| Recruiting | N/A | 380 | Canada, US | Arm 1: treatment with Neovasc Reducer, Arm 2 (control): Implantation procedure with no device implanted, Arm 3 (unblinded, non-randomized): Single arm registry | Neovasc Inc., Shockwave Medical, Inc. | Refractory Angina | 06/25 | 12/28 | | |
NCT05069558: Comparing PFO Outcomes of the Occlutech Flex II PFO Occluder to Standard of Care PFO Occlusion |
|
|
| Active, not recruiting | N/A | 450 | Europe, Canada, US | Investigational PFO Closure Device, Standard of Care PFO Closure Device | Occlutech International AB | Stroke, Patent Foramen Ovale, PFO | 11/25 | 10/26 | | |
AMIHOT III, NCT04743245: Delivery SSO2 Therapy for 60 Min in Anterior MI Patients With PCI ≤ 6 Hours of Symptoms Onset Compared to Standard. |
|
|
| Recruiting | N/A | 434 | US | TherOx DownStream System, PCI | TherOx | Acute Myocardial Infarction, STEMI | 10/25 | 04/26 | | |
| Rogers, Joseph |
DIAGNODE-3, NCT05018585 / 2021-002731-32: A Phase III Study to Investigate If the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed with Type 1 Diabetes |
|
|
| Recruiting | 3 | 330 | Europe, US, RoW | Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®, Diamyd, Colecalciferol 2000 IU, Divisun 2000 IU, Placebo | Diamyd Medical AB | Type 1 Diabetes Mellitus | 12/27 | 12/27 | | |
NCT05592275: A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF) |
|
|
| Active, not recruiting | 2 | 456 | Europe, Canada, Japan, US, RoW | LY3540378, Placebo | Eli Lilly and Company | Heart Failure, Heart Failure With Preserved Ejection Fraction | 01/25 | 01/25 | | |
NCT06174103: BiVACOR® Total Artificial Heart Early Feasibility Study |
|
|
| Recruiting | N/A | 5 | US | BiVACOR TAH System | BiVACOR Inc. | Heart Failure, Biventricular Failure | 08/25 | 12/26 | | |
| Mallidi, Hari |
| Active, not recruiting | N/A | 350 | US | OCS Heart System | TransMedics | Transplant | 12/25 | 12/29 | | |
| Krajcer, Zvonimir |
| Active, not recruiting | N/A | 149 | Europe, US | PerQseal® Closure Device System | Vivasure Medical Limited | Percutaneous Large Hole Vascular Closure | 12/24 | 06/25 | | |
| Civitello, Andrew |
GenePHIT, NCT05598333: Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects with Non-Ischemic NYHA Class III Heart Failure |
|
|
| Recruiting | 2 | 150 | US | AB-1002, Gene Therapy, NAN-101 | Asklepios Biopharmaceutical, Inc. | Congestive Heart Failure | 10/26 | 12/30 | | |
| Chen, James |
| Recruiting | 3 | 164 | Europe, Canada, US, RoW | Tazemetostat, EPZ-6438, IPN60200, Doxorubicin HCl, Tazverik®, Placebo | Epizyme, Inc. | Advanced Soft-tissue Sarcoma, Advanced Epithelioid Sarcoma | 01/29 | 01/30 | | |
|
NCT03233698: Atezolizumab in Treating Patients With Newly Diagnosed and Metastatic Alveolar Soft Part Sarcoma That Cannot Be Removed by Surgery |
|
|
| Recruiting | 2 | 26 | US | Atezolizumab, Laboratory Biomarker Analysis, Pharmacological Study | National Cancer Institute (NCI) | Metastatic Alveolar Soft Part Sarcoma | 12/18 | 12/18 | | |
| Terminated | N/A | 12500 | Europe, Canada, US, RoW | | Arthrex, Inc. | Degenerative and Traumatic Pathology of the Knee, Degenerative and Traumatic Pathology of the Shoulder and Elbow, Degenerative and Traumatic Pathology of the Foot and Ankle, Degenerative and Traumatic Pathology of the Hand and Wrist, Degenerative and Traumatic Pathology of the Hip | 07/23 | 07/23 | | |
| Completed | N/A | 120 | Canada | Bubble blowing (active), Video distraction (passive) | University of British Columbia | Pain, Anxiety | 07/24 | 07/24 | | |
| Gregoric, Igor |
NCT02232659: SynCardia 70cc TAH-t for Destination Therapy (DT) |
|
|
| Recruiting | N/A | 38 | US | 70cc TAH-t for Destination Therapy | SynCardia Systems. LLC | Life-threatening, Biventricular Heart Failure, Ineligible for Cardiac Transplant | 12/21 | 05/22 | | |
| Piece, Nichole |
DCMII, NCT04476901: Administration of Allogeneic-MSC in Patients with Non-Ischemic Dilated Cardiomyopathy |
|
|
| Recruiting | 2 | 136 | US | allogeneic human mesenchymal stem cells (hMSCs), Placebo | Joshua M Hare, United States Department of Defense, The University of Texas Health Science Center, Houston | Non-ischemic Dilated Cardiomyopathy | 12/25 | 12/25 | | |
| Taveras, Yanille |
APEX-AV, NCT05318092: Evaluating the Safety and Efficacy of the AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 PE for Treatment of Acute Pulmonary Embolism |
|
|
| Completed | N/A | 122 | US | AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 PE | Angiodynamics, Inc. | Pulmonary Embolism, Acute Pulmonary Embolism | 01/24 | 01/24 | | |
| Recruiting | N/A | 125 | US | Cleaner Pro Thrombectomy System, Cleaner Vac Thrombectomy System | Argon Medical Devices, NAMSA | Pulmonary Embolism, Acute Pulmonary Embolism, Cardiovascular Diseases, Venous Thromboembolism | 02/26 | 05/26 | | |
| Ono, Masahiro |
| Active, not recruiting | N/A | 1017 | US | Impella 5.5 | Abiomed Inc. | Cardiogenic Shock, Acute Decompensated Heart Failure | 12/24 | 12/24 | | |
| Active, not recruiting | N/A | 350 | US | OCS Heart System | TransMedics | Transplant | 12/25 | 12/29 | | |
| Costello, Brianna |
| Completed | N/A | 685 | Europe, US | Electrocardiogram recording | Withings, Syntactx | Atrial Fibrillation | 08/23 | 08/23 | | |
| Carranza, Sylvia |
DCMII, NCT04476901: Administration of Allogeneic-MSC in Patients with Non-Ischemic Dilated Cardiomyopathy |
|
|
| Recruiting | 2 | 136 | US | allogeneic human mesenchymal stem cells (hMSCs), Placebo | Joshua M Hare, United States Department of Defense, The University of Texas Health Science Center, Houston | Non-ischemic Dilated Cardiomyopathy | 12/25 | 12/25 | | |
| Caceres, Lina |
DCMII, NCT04476901: Administration of Allogeneic-MSC in Patients with Non-Ischemic Dilated Cardiomyopathy |
|
|
| Recruiting | 2 | 136 | US | allogeneic human mesenchymal stem cells (hMSCs), Placebo | Joshua M Hare, United States Department of Defense, The University of Texas Health Science Center, Houston | Non-ischemic Dilated Cardiomyopathy | 12/25 | 12/25 | | |
GenePHIT, NCT05598333: Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects with Non-Ischemic NYHA Class III Heart Failure |
|
|
| Recruiting | 2 | 150 | US | AB-1002, Gene Therapy, NAN-101 | Asklepios Biopharmaceutical, Inc. | Congestive Heart Failure | 10/26 | 12/30 | | |
| Sampaio, Sara |
| Active, not recruiting | 3 | 125 | Canada, US | Autologous cell therapy, Sham | BioCardia, Inc. | Heart Failure, Systolic | 12/24 | 12/26 | | |
| Frank, Felicia |
| Active, not recruiting | 4 | 165 | Europe, Canada, Japan, US, RoW | dabrafenib, DRB436, trametinib, TMT212 | Novartis Pharmaceuticals, Novartis Pharma AG | Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma, Oligodendroglioma, Childhood, Anaplastic Oligodendroglioma, Glioblastoma, Pilocytic Astrocytoma, Giant Cell Astrocytoma, Pleomorphic Xanthoastrocytoma, Anaplastic Pleomorphic Xanthoastrocytoma, Angiocentric Glioma, Chordoid Glioma of Third Ventricle, Gangliocytoma, Ganglioglioma, Anaplastic Ganglioglioma, Dysplastic Gangliocytoma of Cerebrellum, Desmoplastic Infantile Astrocytoma and Ganglioglioma, Papillary Glioneuronal Tumor, Rosette-forming Glioneuronal Tumor, Central Neurocytoma, Extraventricular Neurocytoma, Cerebellar Liponeurocytoma, Neurofibromatosis Type 1 | 05/26 | 05/26 | | |
| Completed | 1 | 30 | Canada, US | Revumenib, SNDX-5613, Chemotherapy Regimen 1, Chemotherapy Regimen 2 | Syndax Pharmaceuticals | Relapsed/Refractory Leukemias, Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia, Mixed Phenotype Acute Leukemia, Acute Myeloid Leukemia, Acute Undifferentiated Leukemia | 07/24 | 07/24 | | |
|
| Chambers, Jennifer |
| Recruiting | N/A | 2300 | US | Outpatient Foley catheter | University of Pennsylvania | Induction of Labor Affected Fetus / Newborn | 06/27 | 06/27 | | |
| Croce, Kevin |
AGENT IDE, NCT06492174: A Clinical Trial to Assess the Agent Paclitaxel Coated PTCA Balloon Catheter for the Treatment of Subjects With In-Stent Restenosis (ISR) - Long Lesion Cohort |
|
|
| Active, not recruiting | 3 | 20 | US | AGENT DCB 40 mm | Boston Scientific Corporation | In-Stent Restenosis | 12/25 | 12/27 | | |
| Completed | N/A | 60 | Canada, US | Ringer Perfusion Balloon Catheter | Vascular Solutions LLC | Coronary Stenosis | 06/23 | 06/23 | | |
| Active, not recruiting | N/A | 418 | Europe, Canada, US, RoW | SELUTION SLR™ DEB, Control | M.A. Med Alliance S.A., Iqvia Pty Ltd, Cordis Corporation | Coronary Restenosis | 07/25 | 08/29 | | |
| Active, not recruiting | N/A | 15 | Europe, US | VITALYST System, Percutaneous Mechanical Circulatory Support | Boston Scientific Corporation | High-risk Percutaneous Coronary Intervention, Heart Disease, Coronary | 10/24 | 01/25 | | |
| Recruiting | N/A | 380 | Canada, US | Arm 1: treatment with Neovasc Reducer, Arm 2 (control): Implantation procedure with no device implanted, Arm 3 (unblinded, non-randomized): Single arm registry | Neovasc Inc., Shockwave Medical, Inc. | Refractory Angina | 06/25 | 12/28 | | |
| Recruiting | N/A | 170 | US | Sapphire 3 Coronary Dilatation Catheter | OrbusNeich, Avania | Coronary Artery Disease, Coronary Disease, Myocardial Ischemia, Heart Diseases, Arteriosclerosis, Cardiovascular Diseases, Chronic Total Occlusion, Chronic Total Occlusion of Coronary Artery | 12/25 | 12/25 | | |
| Active, not recruiting | N/A | 399 | Europe, US | Shockwave Medical Coronary IVL System | Shockwave Medical, Inc. | Coronary Artery Disease | 12/24 | 04/28 | | |
| Mathuria, Nilesh |
LESS-VT, NCT03490201: FLExAbility Sensor Enabled Substrate Targeted Ablation for the Reduction of VT Study |
|
|
| Completed | N/A | 592 | Europe, US, RoW | Market Approved RF Ablation System, FlexAbility SE Ablation Catheter | Abbott Medical Devices | Ventricular Tachycardia | 04/24 | 04/24 | | |
| Kumar, Abhishek |
| Completed | 3 | 287 | US, RoW | Crofelemer 125 MG [Mytesi], Placebo | Napo Pharmaceuticals, Inc. | Cancer Therapy-Related Diarrhea, Chemotherapy-related Diarrhea, Adult Solid Tumor, Prophylaxis of Diarrhea, Symptomatic Relief of Diarrhea, Targeted Therapy-related Diarrhea | 08/23 | 10/23 | | |
| Recruiting | 3 | 500 | US | Anticoagulant Therapy, Catheter-Directed Therapy | NYU Langone Health, National Heart, Lung, and Blood Institute (NHLBI) | Pulmonary Embolism | 01/27 | 01/28 | | |
| Recruiting | N/A | 125 | US | Obsidio™ Conformable Embolic | Boston Scientific Corporation | Hypervascular Tumors, Bleeding, Hemorrhage | 06/25 | 06/25 | | |
| Recruiting | N/A | 125 | US | Cleaner Pro Thrombectomy System, Cleaner Vac Thrombectomy System | Argon Medical Devices, NAMSA | Pulmonary Embolism, Acute Pulmonary Embolism, Cardiovascular Diseases, Venous Thromboembolism | 02/26 | 05/26 | | |
NCT05915468: Large De-NOVo Coronary artEry Disease Treated With Sirolimus Drug Eluting Balloon (LOVE DEB) |
|
|
| Recruiting | N/A | 300 | Europe | | Wrightington, Wigan and Leigh NHS Foundation Trust, Professor Azfar Zaman - Freeman Hospital, Newcastle | Coronary Artery Disease | 07/25 | 07/26 | | |
| Active, not recruiting | N/A | 85 | Europe | BioMatrix Alpha | Biosensors Europe SA | Coronary Artery Disease | 07/25 | 03/26 | | |
| Makam |
| Active, not recruiting | 3 | 9541 | Europe, Canada, Japan, US, RoW | Obicetrapib, Placebo | NewAmsterdam Pharma, Monash University | Atherosclerotic Cardiovascular Disease | 11/26 | 11/26 | | |
| Postilian, Alex |
| Completed | N/A | 650 | Europe, US | Electrocardiogram recording | Withings, Syntactx | Atrial Fibrillation | 09/23 | 09/23 | | |
| Worley, Amy |
NCT05143177: A Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient's Calcific Aortic Valve Disease with Mild to Moderate Aortic Stenosis (EVOID-AS) |
|
|
| Active, not recruiting | 2/3 | 867 | Canada, US | Evogliptin, DA-1229, Placebo | REDNVIA Co., Ltd. | Calcific Aortic Valve Disease | 05/26 | 12/26 | | |
ADVANTAGE AF, NCT05443594: A Prospective Single Arm Open Label Study of the FARAPULSE Pulsed Field Ablation System in Subjects with Persistent Atrial Fibrillation |
|
|
| Active, not recruiting | N/A | 669 | Europe, Canada, US | Phase 1: FARAPULSE Ablation System, Phase 2: FARAPULSE Ablation System | Boston Scientific Corporation | Persistent Atrial Fibrillation | 03/25 | 03/25 | | |
| Belknap, Anthony |
| Recruiting | N/A | 1247 | Europe, Canada, US | Edwards PASCAL System, Transcatheter Mitral Valve repair (TMVr), Abbott Mitraclip System | Edwards Lifesciences | Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation | 01/25 | 04/30 | | |
NCT05677100: Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure |
|
|
| Recruiting | N/A | 268 | US | Aortix System, Aortix Pump | Procyrion | Heart Failure, Cardiorenal Syndrome, Cardio-Renal Syndrome, ADHF, Heart Failure, Systolic, Heart Failure, Diastolic, Heart Failure; With Decompensation, Heart Failure, Congestive | 07/25 | 12/25 | | |
NCT05069558: Comparing PFO Outcomes of the Occlutech Flex II PFO Occluder to Standard of Care PFO Occlusion |
|
|
| Active, not recruiting | N/A | 450 | Europe, Canada, US | Investigational PFO Closure Device, Standard of Care PFO Closure Device | Occlutech International AB | Stroke, Patent Foramen Ovale, PFO | 11/25 | 10/26 | | |
NCT03970343: Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy |
|
|
| Recruiting | N/A | 620 | US | OPTIMIZER Smart System | Impulse Dynamics | Heart Failure | 03/26 | 03/26 | | |
| Munson, Taylor |
JUPITER, NCT05762302: The Impact of MeMed BV® on Management of Patients With Suspected Lower Respiratory Tract Infections (LRTI) in the Emergency Department (ED) and Urgent Care Center (UCC) ("" TRIAL) |
|
|
| Recruiting | N/A | 1316 | US, RoW | MeMed BV test | MeMed Diagnostics Ltd. | Lower Respiratory Tract Infection | 02/25 | 02/25 | | |
| Active, not recruiting | N/A | 15 | Europe, US | VITALYST System, Percutaneous Mechanical Circulatory Support | Boston Scientific Corporation | High-risk Percutaneous Coronary Intervention, Heart Disease, Coronary | 10/24 | 01/25 | | |
| Recruiting | N/A | 380 | Canada, US | Arm 1: treatment with Neovasc Reducer, Arm 2 (control): Implantation procedure with no device implanted, Arm 3 (unblinded, non-randomized): Single arm registry | Neovasc Inc., Shockwave Medical, Inc. | Refractory Angina | 06/25 | 12/28 | | |
| Active, not recruiting | N/A | 399 | Europe, US | Shockwave Medical Coronary IVL System | Shockwave Medical, Inc. | Coronary Artery Disease | 12/24 | 04/28 | | |
| Houston, Jada |
NCT05143177: A Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient's Calcific Aortic Valve Disease with Mild to Moderate Aortic Stenosis (EVOID-AS) |
|
|
| Active, not recruiting | 2/3 | 867 | Canada, US | Evogliptin, DA-1229, Placebo | REDNVIA Co., Ltd. | Calcific Aortic Valve Disease | 05/26 | 12/26 | | |
| Marbach, Jeffrey |
NCT05677100: Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure |
|
|
| Recruiting | N/A | 268 | US | Aortix System, Aortix Pump | Procyrion | Heart Failure, Cardiorenal Syndrome, Cardio-Renal Syndrome, ADHF, Heart Failure, Systolic, Heart Failure, Diastolic, Heart Failure; With Decompensation, Heart Failure, Congestive | 07/25 | 12/25 | | |
| Jackson, Joseph |
NCT05677100: Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure |
|
|
| Recruiting | N/A | 268 | US | Aortix System, Aortix Pump | Procyrion | Heart Failure, Cardiorenal Syndrome, Cardio-Renal Syndrome, ADHF, Heart Failure, Systolic, Heart Failure, Diastolic, Heart Failure; With Decompensation, Heart Failure, Congestive | 07/25 | 12/25 | | |
